Biotechnology earnings: latest results compared
The latest quarter from Regeneron, Vertex Pharmaceuticals, Moderna, Biogen and Alnylam, side by side. Revenue is as reported; growth and operating margin are calculated from XBRL filings once the 10-Q or 10-K is in.
| Latest quarter | Revenue | Growth vs year ago | Operating margin | Reported |
|---|---|---|---|---|
| $5.1B | +36.3% | 40.0% | 30 Oct 2026 | |
Vertex Pharmaceuticals Q3 2026 | $3.4B | +11.8% | 20.7% | 2 Nov 2026 |
| $1.3B | +29.2% | 9.9% | 6 Nov 2026 | |
| $2.8B | +10.6% | — | 28 Oct 2026 | |
Alnylam Q3 2026 | $1.5B | +16.7% | 23.7% | 29 Oct 2026 |
What each company reported
- 6 Nov 2026
Moderna Q3 2026 · Moderna won FDA approval for mFLUSIVA, its fifth approved product and the first mRNA flu vaccine, and reported positive Phase 3 intismeran melanoma results…Transcript · Slides
- 2 Nov 2026
Vertex Pharmaceuticals Q3 2026 · Vertex closed its Crinetics acquisition, adding rare endocrine as a fourth commercial pillar, and now awaits a November 30 FDA decision on povetacicept that…Transcript - 30 Oct 2026
Regeneron Q3 2026 · Regeneron expanded its Sanofi alliance to add four Regeneron-invented, long-acting next-generation immunology antibodies meant to build on Dupixent, backed by…Transcript
- 29 Oct 2026
Alnylam Q3 2026 · Alnylam enlarged its TRITON-CM nucresiran trial to about 2,250 patients, keeping a 2030 ATTR-CM launch, while AMVUTTRA's cardiomyopathy launch kept driving TTR…Summary · Slides - 28 Oct 2026
Biogen Q3 2026 · Biogen's first full quarter with Apellis' eye and kidney drugs pushed growth products to 63% of core pharmaceutical revenue, ahead of December Phase 3 lupus…Transcript
Every quarter and KPI history
Regeneron (REGN)Vertex Pharmaceuticals (VRTX)Moderna (MRNA)Biogen (BIIB)Alnylam (ALNY)